In the second cohort, we monitored HCC growth by bioluminescent imaging of live animals and observed a significant anti-tumor effect of sorafenib treatment in Lifrfl/fl mice (P = 0.0002), but not in Lifrfl/fl;Alb-Cre mice (P = 0.09, Fig. 2e). Here, ALB is linked to hepatocellular carcinoma.